Rimegepant for the acute treatment of migraine in adults from China

被引：0
|
作者：
Yu, S. [1 ]
Guo, A. [2 ]
Zhang, M. [1 ]
Wang, Z. [3 ]
Liu, J. [4 ]
Tan, G. [5 ]
Yang, Q. [6 ]
Liu, Y. [7 ]
Zhao, Q. [8 ]
Lu, Z. [9 ]
Atkinson, J. [10 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] Yanan Univ, Xianyang Hosp, Xianyang, Peoples R China
[3] Changsha Cent Hosp, Changsha, Peoples R China
[4] Wuhan Third Hosp, Wuhan, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[6] Shanxi Prov Hosp, Xian, Peoples R China
[7] Pfizer Inc, Beijing, Peoples R China
[8] Pfizer Inc, Chengdu, Peoples R China
[9] Pfizer China Res & Dev Ltd, Shanghai, Peoples R China
[10] Pfizer LTD, Tadworth, England
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P030
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Rimegepant 75 mg for the Acute Treatment of Migraine in Adults With Frequent Migraine: Long-Term Safety and Clinical Improvement Versus Baseline
    Mullin, Kathleen
    Hutchinson, Susan
    Smith, Timothy
    Lipton, Richard
    Jensen, Christopher
    Leroue, Chelsea
    Thiry, Alexandra
    Lovegren, Meghan
    Conway, Charles
    Coric, Vlad
    Croop, Robert
    NEUROLOGY, 2021, 96 (15)
  • [22] Rimegepant 75 mg for the Acute Treatment of Migraine in Adults With Frequent Migraine: Long-Term Safety and Clinical Improvement Versus Baseline
    Mullin, K.
    Hutchinson, S.
    Smith, T.
    Jensen, C. M.
    Leroue, C.
    Thiry, A.
    Lovegren, M.
    Conway, C. M.
    Coric, V.
    Croop, R.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 102 - 103
  • [23] Rimegepant 75 mg for the acute treatment of migraine in adults with frequent migraine: Long-term safety and clinical improvement versus baseline
    Mullin, K.
    Hutchinson, S.
    Smith, T. R.
    Lipton, R. B.
    Jensen, C. M.
    Leroue, C.
    Thiry, A. C.
    Lovegren, M.
    Conway, C. M.
    Coric, V
    Croop, R.
    HEADACHE, 2021, 61 : 143 - 144
  • [24] Prior migraine treatments among patients initiating rimegepant for acute migraine treatment in the United States
    Brown, J.
    Jenkins, A.
    Blakeman, Hygge K.
    Lipton, R.
    HEADACHE, 2023, 63 : 74 - 74
  • [25] Acute Migraine Treatment in Adults
    Becker, Werner J.
    HEADACHE, 2015, 55 (06): : 778 - 793
  • [26] Rimegepant 75mg for the Acute Treatment of Migraine in Adults With Frequent Migraine: Long-Term Safety and Clinical Improvement Versus Baseline
    Mullin, K.
    Hutchinson, S.
    Smith, T.
    Jensen, C. M.
    Leroue, C.
    Thiry, A.
    Lovegren, M.
    Conway, C. M.
    Coric, V.
    Croop, R.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 152 - 153
  • [27] Rimegepant for migraine: acute efficacy beyond the USA
    Mitsikostas, Dimos
    LANCET NEUROLOGY, 2023, 22 (06): : 456 - 457
  • [28] Rimegepant for migraine
    不详
    AUSTRALIAN PRESCRIBER, 2024, 47 (04) : 134 - 135
  • [29] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
    Jensen, Christopher M.
    Lipton, Richard B.
    Blumenfeld, Andrew
    Croop, Robert
    Thiry, Alexandra
    L'Italien, Gilbert
    Morris, Beth A.
    Coric, Vladimir
    Goadsby, Peter J.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 116 - 117
  • [30] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
    Jensen, C. M.
    Lipton, R.
    Blumenfeld, A.
    Croop, R.
    Thiry, A. C.
    L'Italien, G.
    Morris, B.
    Coric, V.
    Goadsby, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
12345